广告Discover A New TROP2-Directed ADC For HR+ HER2- Unresectable Or Metastatic Breast Cancer. Is A New Therapy For HR+ HER2- mBC An Option For Your Patients? View The MOA To Learn More

广告High homogeneity. Suitable for immunization, neutralizing antibody screening and more. High homogeneity and bioactivity verified. Protocols offered for free.